You have no items in your shopping cart.
X-Ray Confirmed Crystal Form for Peak PLX-3397 Activity and Consistency
Description
Pexidartinib (PLX-3397) is a potent, orally active, and ATP-competitive inhibitor of colony stimulating factor 1 receptor (CSF1R/M-CSFR) and c-Kit, with IC₅₀ values of 20 nM and 10 nM, respectively. It displays 10- to 100-fold selectivity for CSF1R and c-Kit over related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and demonstrates strong anti-tumor activity in research models.
Crystal Form Verified by X-ray Diffraction (XRD)
PLX-3397 obtained from different suppliers can display different crystalline forms, which may lead to notable variations in biological activity, solubility, stability, and experimental reproducibility.
Biofargo’s PLX-3397 is confirmed by X-ray diffraction (XRD) to be a high-activity and highly stable crystal form, ensuring:
-
Consistent lot-to-lot performance
-
Highly reproducible experimental outcomes
-
Superior biological activity compared with non-verified crystal forms
-
Reliable solubility behavior across assays
For research use only. We do not sell to patients.
Specification
| CAS No. | 1029044-16-3 |
| Synonyms | PLX3397 |
| Molecular Formula | C20H15ClF3N5 |
| Formula Weight | 417.81 |
| Purity | ≥98% |
| Formulation | A crystalline solid |
| Solubility | DMF: 20 mg/ml DMF:PBS (pH 7.2) (1:3): 0.25 mg/ml DMSO: 20 mg/ml |
| Color |
Off-white to light yellow
|
| SMILES | ClC1=CC2=C(N=C1)NC=C2CC3=CN=C(NCC4=CN=C(C(F)(F)F)C=C4)C=C3 |
| InChi Code | InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29) |
| InChi Key | JGWRKYUXBBNENE-UHFFFAOYSA-N |
Documents
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.

